A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC

评估预防效果的双盲、随机、对照 III 期研究

• 批准号: 7952038
• 负责人: Gregory James Mertz
• 金额: $ 7.43万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7952038
• 关键词: Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Development; Double-Blind Method; Funding; Grant; Herpesvirus 1; Human Herpesvirus 2; Institution; New Mexico; Phase III Clinical Trials; Randomized; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Universities; Vaccines; Woman; genital herpes

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this research is to determine whether the study vaccine protects women who are HSV-1 [herpes simplex virus] and HSV-2 negative against the development of genital herpes

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的主要目的是确定该研究疫苗是否保护HSV-1 [单纯疱疹病毒]和HSV-2负面的女性，以抗生殖器疱疹的发展